DiscGenics, Inc.

Quick facts

Phase 3 pipeline

• IDCT (rebonuputemcel) · Orthopedics / Spine
  IDCT (rebonuputemcel) is an allogeneic juvenile chondrocyte cell therapy designed to regenerate cartilage and restore joint function in degenerative disc disease.

Phase 1 pipeline

• IDCT

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• DiscGenics, Inc. portfolio CI brief
• DiscGenics, Inc. pipeline updates RSS